Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 984 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: METHOTREXATE Clear all
Completed Phase 2 Interventional Results available

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

NCT02412670
View directory record Official record
Conditions
High Grade Upper Tract Urothelial Carcinoma
Interventions
Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine, Carboplatin, Pegfilgrastim, Nephroureterectomy
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
134
States / cities
Birmingham, Alabama • Aurora, Colorado • Colorado Springs, Colorado + 93 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

NCT03699631
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Tacrolimus, Methotrexate, Tocilizumab
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

NCT00878254
View directory record Official record
Conditions
Mantle-Cell Lymphoma
Interventions
G-CSF, Rituximab, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Ifosfamide, Leucovorin, Mesna, Methotrexate, Vincristine
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 3 Interventional Results available

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

NCT03959241
View directory record Official record
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
Interventions
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

NCT02779283
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Idarubicin, Idelalisib, In Vitro Kinase Inhibitor Assay, Leucovorin Calcium, Methotrexate, Methylprednisolone Sodium Succinate, Ponatinib Hydrochloride, Rituximab, Ruxolitinib Phosphate, Sorafenib Tosylate, Sunitinib Malate, Vincristine Sulfate
Drug · Device · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting Phase 1 Interventional

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma

NCT04656431
View directory record Official record
Conditions
Primary CNS Lymphoma
Interventions
Hyperpolarized pyruvate (13C), Magnetic resonance imaging (MRI)
Drug · Procedure
Lead sponsor
James Rubenstein
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma

NCT00586846
View directory record Official record
Conditions
Osteosarcoma
Interventions
Cisplatin, Doxorubicin, Methotrexate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

NCT04628767
View directory record Official record
Conditions
Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Pegfilgrastim, Therapeutic Conventional Surgery, Vinblastine Sulfate
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
257
States / cities
Kingman, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 197 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

NCT00589563
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Secondary Myelofibrosis, Small Intestine Cancer
Interventions
anti-thymocyte globulin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, methotrexate, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Phoenix, Arizona • Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

NCT01888874
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GLPG0634, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
28
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

NCT00857389
View directory record Official record
Conditions
Stem Cell Transplantation, Leukemia, Lymphoma
Interventions
Thiotepa, Clofarabine, Busulfan, Allogeneic Stem Cell Transplantation, Thymoglobulin (ATG), G-CSF (Filgrastim), Tacrolimus, Methotrexate, Cyclophosphamide, Mesna
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia

NCT00003783
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, idarubicin, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
51
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Results available

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

NCT03792256
View directory record Official record
Conditions
Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma, T-cell Leukemia, Recurrent Disease, Acute Leukemia
Interventions
Palbociclib, Cytarabine, Methotrexate, Hydrocortisone, Doxorubicin, Prednisolone, Vincristine, Pegaspargase, Prednisone
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 31 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Loma Linda, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

NCT02611037
View directory record Official record
Conditions
Malignant Pleural Mesothelioma, Mesothelioma
Interventions
Cisplatin, Methotrexate, Gemcitabine, Lung Cancer Symptom Scale for Mesothelioma Questionnaire
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate

NCT01329991
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PLX5622, Placebo
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Anniston, Alabama • Lansing, Michigan • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

NCT01185353
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
LY3009104, Placebo, Methotrexate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
31
States / cities
Paradise Valley, Arizona • Peoria, Arizona • Covina, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma

NCT00221325
View directory record Official record
Conditions
Central Nervous System Lymphoma, Intraocular Lymphoma
Interventions
Intraventricular Rituximab Plus MTX
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Early Phase 1 Interventional

Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation

NCT00612274
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
tacrolimus, Sirolimus, Methotrexate
Drug
Lead sponsor
Yale University
Other
Eligibility
16 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

NCT01389076
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Bexxar, Low Dose Methotrexate
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional Results available

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

NCT02420717
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Ph-Like Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin, Laboratory Biomarker Analysis, Leucovorin, Mercaptopurine, Methotrexate, Prednisone, Rituximab, Ruxolitinib Phosphate, Vincristine
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 22, 2026, 2:34 PM EDT
Not listed Phase 4 Interventional

Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)

NCT02188017
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Sarcoidosis
Interventions
Acthar gel
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

NCT00282308
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab, Methotrexate, Methylprednisone, C. albicans, Tetanus toxoid adsorbed booster vaccine, 23-valent pneumococcal polysaccharide vaccine, Keyhole limpet hemocyanin
Drug · Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting Phase 2 Interventional

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

NCT06390319
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
Interventions
Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Dasatinib, Venetoclax, Bortezomib, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Methotrexate, Thioguanine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
4
States / cities
San Diego, California • Charlotte, North Carolina • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

NCT00301834
View directory record Official record
Conditions
Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia, Myelodysplastic Syndromes, Severe Congenital Neutropenia
Interventions
alemtuzumab, busulfan, cyclosporine, fludarabine phosphate, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
San Francisco, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 22, 2026, 2:34 PM EDT